Negara: Kanada
Bahasa: Inggris
Sumber: Health Canada
PERINDOPRIL ERBUMINE
ANGITA PHARMA INC.
C09AA04
PERINDOPRIL
2MG
TABLET
PERINDOPRIL ERBUMINE 2MG
ORAL
100/500
Prescription
ANGIOTENSIN-CONVERTING ENZYME INHIBITORS
Active ingredient group (AIG) number: 0127178001; AHFS:
APPROVED
2018-10-16
_AG-Perindopril (Perindopril Erbumine Tablets) Product Monograph_ _ _ _Page 1 of 64 _ PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION PR AG-PERINDOPRIL Perindopril Erbumine Tablets Tablets, 2 mg, 4 mg and 8 mg, Oral USP Angiotensin Converting Enzyme Inhibitor Angita Pharma Inc. 1310 rue Nobel Boucherville, Quebec J4B 5H3, Canada Submission Control Number: 276805 Date of Initial Authorization: OCT 16, 2018 Date of Revision: JUL 25, 2023 _AG-Perindopril (Perindopril Erbumine Tablets) Product Monograph_ _ _ _Page 2 of 64 _ RECENT MAJOR LABEL CHANGES 2 CONTRAINDICATIONS 07/2023 7 WARNINGS AND PRECAUTIONS 07/2023 TABLE OF CONTENTS SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF AUTHORIZATION ARE NOT LISTED . RECENT MAJOR LABEL CHANGES ............................................................................................................... 2 TABLE OF CONTENTS .................................................................................................................................. 2 PART I: HEALTH PROFESSIONAL INFORMATION ....................................................................... 4 1 INDICATIONS ............................................................................................................... 4 1.1 Pediatrics (< 18 years of age) ............................................................................................................ 4 1.2 Geriatrics (>65 years of age) ............................................................................................................. 4 2 CONTRAINDICATIONS .................................................................................................. 4 3 SERIOUS WARNINGS AND PRECAUTIONS BOX ............................................................. 5 4 DOSAGE AND ADMINISTRATION .................................................................................. 5 4.1 Dosing Considerations ...................................................................................................................... 5 Baca dokumen lengkapnya